NASDAQ:INAB IN8bio (INAB) Stock Price, News & Analysis → top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (From Traders Agency) (Ad) Free INAB Stock Alerts $1.06 +0.02 (+1.92%) (As of 04/24/2024 ET) Add Compare Share Share Today's Range$1.01▼$1.0750-Day Range$0.95▼$1.3052-Week Range$0.65▼$3.48Volume151,765 shsAverage Volume314,937 shsMarket Capitalization$33.91 millionP/E RatioN/ADividend YieldN/APrice Target$10.75 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get IN8bio alerts: Email Address IN8bio MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside914.2% Upside$10.75 Price TargetShort InterestHealthy0.18% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.99Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.70) to ($0.42) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.63 out of 5 starsMedical Sector248th out of 907 stocksBiological Products, Except Diagnostic Industry37th out of 153 stocks 3.5 Analyst's Opinion Consensus RatingIN8bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageIN8bio has only been the subject of 2 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.18% of the float of IN8bio has been sold short.Short Interest Ratio / Days to CoverIN8bio has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in IN8bio has recently decreased by 39.15%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldIN8bio does not currently pay a dividend.Dividend GrowthIN8bio does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for INAB. Previous Next 3.3 News and Social Media Coverage News SentimentIN8bio has a news sentiment score of 0.99. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.44 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for IN8bio this week, compared to 1 article on an average week.Search InterestOnly 4 people have searched for INAB on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat Follows2 people have added IN8bio to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, IN8bio insiders have not sold or bought any company stock.Percentage Held by Insiders33.00% of the stock of IN8bio is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions92.05% of the stock of IN8bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for IN8bio are expected to grow in the coming year, from ($0.70) to ($0.42) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of IN8bio is -1.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of IN8bio is -1.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioIN8bio has a P/B Ratio of 1.36. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Paradigm PressForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISYou might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.Click here to find out that this 8,788% cryptocurrency is. About IN8bio Stock (NASDAQ:INAB)IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidates include INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation; and INB-400, which is in Phase 2 clinical trial to treat newly diagnosed GBM. It also develops INB-300, INB-410, and INB-500 that are in preclinical Phase for treatment of various solid tumor cancers. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is headquartered in New York, New York.Read More INAB Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart INAB Stock News HeadlinesApril 25, 2024 | americanbankingnews.comEquities Analysts Set Expectations for IN8bio, Inc.'s Q1 2024 Earnings (NASDAQ:INAB)April 24, 2024 | globenewswire.comIN8bio Announces Oral Presentation at the Upcoming American Society of Gene & Cell Therapy (ASGCT) 2024 Annual MeetingApril 25, 2024 | Paradigm Press (Ad)Bitcoin Rockets To Record High But Buy THIS InsteadRecently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…April 22, 2024 | finance.yahoo.comINAB: Initiating Coverage – Enhancing the Insurgents of the Immune SystemApril 16, 2024 | globenewswire.comIN8bio to Present at Noble Capital Markets Emerging Growth Virtual Healthcare Equity ConferenceApril 12, 2024 | markets.businessinsider.comPromising Preclinical Data Underpins Buy Rating for IN8bio’s nsCAR PlatformApril 10, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: TRACON Pharmaceuticals (TCON) and IN8bio (INAB)April 10, 2024 | msn.comKill Leukemia Cells While Preserving Healthy Tissues: Nano-Cap Cancer Focused Firm IN8bio's Preclinical Candidate Shows PotentialApril 25, 2024 | Paradigm Press (Ad)Bitcoin Rockets To Record High But Buy THIS InsteadRecently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…April 9, 2024 | globenewswire.comIN8bio Announces New Preclinical Data for Gamma-Delta nsCAR-T Cell Therapy Platform at AACR 2024March 28, 2024 | finance.yahoo.comWe're Keeping An Eye On IN8bio's (NASDAQ:INAB) Cash Burn RateMarch 20, 2024 | investing.comLaidlaw sets INAB stock to buy, targets $7.50 priceMarch 14, 2024 | investorplace.comINAB Stock Earnings: IN8bio Misses EPS for Q4 2023March 14, 2024 | globenewswire.comIN8bio Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Business HighlightsMarch 13, 2024 | markets.businessinsider.comBuy Recommendation Based on IN8bio’s Promising γ δ T Cell Therapy Developments and Positive Clinical Trial OutcomesMarch 5, 2024 | globenewswire.comIN8bio to Present New Preclinical Data on Novel Gamma-Delta CAR Platform Candidate at AACR Annual Meeting 2024February 26, 2024 | businesswire.comIN8bio to Present at Upcoming Investor ConferencesFebruary 14, 2024 | finanznachrichten.deIN8bio, Inc: IN8bio Announces Publication on Novel Gamma-Delta T Cell Therapy for Glioblastoma in Frontiers in ImmunologyFebruary 14, 2024 | finance.yahoo.comIN8bio Announces Publication on Novel Gamma-Delta T Cell Therapy for Glioblastoma in Frontiers in ImmunologyFebruary 14, 2024 | globenewswire.comIN8bio Announces Publication on Novel Gamma-Delta T Cell Therapy for Glioblastoma in Frontiers in ImmunologyFebruary 13, 2024 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Adaptimmune Therapeutics (ADAP), CymaBay Therapeutics (CBAY)January 4, 2024 | msn.comIn8bio stock jumps 11% following clinical updateJanuary 4, 2024 | finance.yahoo.comIN8bio Highlights Recent Company Accomplishments and Outlines 2024 Pipeline GoalsDecember 18, 2023 | ca.finance.yahoo.comIN8bio, Inc. (INAB) Stock Price, News, Quote & History - Yahoo FinanceDecember 14, 2023 | markets.businessinsider.comBuy Rating for IN8bio Amidst Promising Leukemia Treatment Advances and Robust Clinical DataDecember 11, 2023 | finance.yahoo.comIN8bio Announces Pricing of Financing Totaling up to $46.9 Million in Private PlacementDecember 7, 2023 | finanznachrichten.deIN8bio, Inc: IN8bio Appoints Dr. Corinne Epperly to Board of DirectorsSee More Headlines Receive INAB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for IN8bio and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/14/2024Today4/24/2024Next Earnings (Estimated)5/10/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:INAB CUSIPN/A CIK1740279 Webwww.in8bio.com Phone646-600-6438FaxN/AEmployees31Year FoundedN/APrice Target and Rating Average Stock Price Target$10.75 High Stock Price Target$14.00 Low Stock Price Target$7.50 Potential Upside/Downside+914.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($1.01) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-30,010,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-147.67% Return on Assets-105.00% Debt Debt-to-Equity Ratio0.02 Current Ratio4.57 Quick Ratio4.57 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.78 per share Price / Book1.36Miscellaneous Outstanding Shares31,990,000Free Float21,434,000Market Cap$33.91 million OptionableNot Optionable Beta-0.01 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Tai-Wei Ho (Age 47)Co-Founder, President, CEO & Director Comp: $837kDr. Kate Rochlin Ph.D. (Age 43)Chief Operating Officer Comp: $565.4kDr. Trishna Goswami M.D. (Age 46)Chief Medical Officer Comp: $638.51kDr. Lawrence S. Lamb Ph.D. (Age 70)Executive VP, Co-Founder & Chief Scientific Officer Comp: $482.47kMr. Patrick McCall CPA (Age 41)CFO & Secretary Comp: $519.35kMr. Michael McNamaraVice President of AccountingMore ExecutivesKey CompetitorsProtara TherapeuticsNASDAQ:TARACortexymeNASDAQ:CRTXCyclo TherapeuticsNASDAQ:CYTHAchilles TherapeuticsNASDAQ:ACHLOrphazyme A/SNASDAQ:ORPHView All CompetitorsInsiders & InstitutionsAIGH Capital Management LLCBought 4,098,361 shares on 2/12/2024Ownership: 12.811%Texas Capital Bank Wealth Management Services IncBought 36,179 shares on 2/8/2024Ownership: 0.246%Sigma Planning CorpSold 152,820 shares on 2/1/2024Ownership: 0.413%Voss Capital LLCSold 170,375 shares on 1/30/2024Ownership: 1.067%Jeremy R GraffBought 2,500 shares on 9/13/2023Total: $2,375.00 ($0.95/share)View All Insider TransactionsView All Institutional Transactions INAB Stock Analysis - Frequently Asked Questions Should I buy or sell IN8bio stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for IN8bio in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" INAB shares. View INAB analyst ratings or view top-rated stocks. What is IN8bio's stock price target for 2024? 2 brokerages have issued 12 month price objectives for IN8bio's shares. Their INAB share price targets range from $7.50 to $14.00. On average, they expect the company's share price to reach $10.75 in the next year. This suggests a possible upside of 914.2% from the stock's current price. View analysts price targets for INAB or view top-rated stocks among Wall Street analysts. How have INAB shares performed in 2024? IN8bio's stock was trading at $1.38 at the start of the year. Since then, INAB stock has decreased by 23.2% and is now trading at $1.06. View the best growth stocks for 2024 here. Are investors shorting IN8bio? IN8bio saw a decrease in short interest in March. As of March 31st, there was short interest totaling 51,600 shares, a decrease of 39.2% from the March 15th total of 84,800 shares. Based on an average daily trading volume, of 168,200 shares, the days-to-cover ratio is presently 0.3 days. Approximately 0.2% of the company's shares are sold short. View IN8bio's Short Interest. When is IN8bio's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024. View our INAB earnings forecast. How were IN8bio's earnings last quarter? IN8bio, Inc. (NASDAQ:INAB) announced its quarterly earnings results on Thursday, March, 14th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.16) by $0.05. When did IN8bio IPO? IN8bio (INAB) raised $44 million in an initial public offering on Friday, July 30th 2021. The company issued 4,000,000 shares at a price of $10.00-$12.00 per share. B. Riley Securities acted as the underwriter for the IPO. How do I buy shares of IN8bio? Shares of INAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:INAB) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersHe Is Giving Away BitcoinCrypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm Presstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American AlternativeEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsFed launches fourth dollar overhaulStansberry ResearchGreat Crypto BullWeiss RatingsMan Who Predicted 2008: “This Will be Worse.”Altimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IN8bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
